Clinical trials: Radical Cure
Prostate Cancer, Physical Activity
Exercise for Improving Prostate Oxygenation in Prostate Tumors (Exipox)
Previous research into metabolic and hypoxic markers has found evidence of preclinical impact of exercise on prostate tumor blood flow and oxygenation in rodents .
- Conditions
- Prostate Cancer, Physical Activity, Hypoxia
- Trial name
- EXIPOX (NCT03365076)
- Testing
- Physical activity
- Where
- Norway
- Volunteers
- 1 people
- Sponsor
- University Hospital of North Norway
Uncomplicated Malaria
Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria
Plasmodium vivax is the most geographically widespread malaria species and the second largest contributor to symptomatic malaria worldwide.
- Trial name
- NCT07403643
- Testing
- Single dose tafenoquine (10 mg/kg), Dihydroartemisinin-piperaquine (DHA-PPQ), Artemether + Lumefantrine
- Where
- Papua New Guinea
- Volunteers
- 60 people
- Sponsor
- Curtin University
Vivax Malaria
Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure
The study will be an open-labelled randomized clinical trial to determine therapeutic efficacy. Note that this will not be an Investigational New Drug application, as only World Health Organization (WHO)-approved drugs will be…
- Trial name
- NCT04706130
- Testing
- Primaquine, Artesunate
- Where
- Cambodia
- Volunteers
- 160 people
- Sponsor
- University of Maryland, Baltimore
Colorectal Cancer, Retroperitoneal Lymph Node Metastasis
CRT Versus Surgery for Retroperitoneal or Paraaortic Lymph Node Recurrence of CRC
The study aims to compare the effects of chemoradiation versus radical surgery in treating retro-peritoneal or para-aortic lymph node metastasis in colorectal cancer.
- Conditions
- Colorectal Cancer, Retroperitoneal Lymph Node Metastasis, Para-aortic Lymph Node Metastasis
- Trial name
- NCT03725254
- Testing
- lymphadenectomy, chemoradiotherapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Fudan University
Malaria, Vivax, G6PD Deficiency
Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil
This is an observational study carried out in Brazil in patients with P. vivax malaria. The study will be carried out in the municipalities of Manaus (state of Amazonas) and Porto Velho (state of Rondônia).
- Trial name
- Trust (NCT05096702)
- Testing
- Tafenoquine, Primaquine
- Where
- 41 sites in Brazil
- Volunteers
- 16,000 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Plasmodium Vivax Malaria
Southeast Asia Dose Optimization of Tafenoquine
Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the…
- Trial name
- SEADOT (NCT04704999)
- Testing
- Tafenoquine, Chloroquine, Artemether 20 mg-Lumefantrine 120 mg
- Where
- 6 sites in Cambodia, Indonesia and 3 more
- Volunteers
- 820 people
- Sponsor
- University of Oxford
Nasopharyngeal Cancer, Neoplasm Metastasis
Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions
Oligo-metastases NPC patients received radiation for primary tumors and treatments for metastatic lesions.
- Trial name
- NCT03129412
- Testing
- radical radiotherapy
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Zhejiang Cancer Hospital
Malaria, Vivax, Relapse
Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia
Primaquine (PQ) is the only widely available treatment to prevent P. vivax relapses. World Health Organization recommends increased PQ doses in East Asia and Oceania, frequently relapsing strains.
- Trial name
- NCT05232227
- Testing
- Primaquine double dose over 14 days, Primaquine single dose over 14 days
- Sponsor
- University of California, San Francisco
Esophageal Squamous Cell Carcinoma, Chemotherapy Effect
Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC
This study is a phase III, multicenter, prospective randomized controlled clinical study comparing the efficacy of non-surgical esophageal squamous cell carcinoma with radical chemoradiotherapy and radical chemoradiotherapy…
- Conditions
- Esophageal Squamous Cell Carcinoma, Chemotherapy Effect, Side Effect of Drug
- Trial name
- NCT05775419
- Testing
- Consolidation chemotherapy (4 courses), Concurrent chemotherapy (2 courses)
- Where
- China
- Volunteers
- 1,216 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatocellular Carcinoma
Effect of I/R Injuries by Pringle Manoeuvre on the Prognosis of HCC Patients After Curative Hepatectomy
This is a multi-centre prospective randomized controlled trial to explore the influence of ischemia-reperfusion injuries elicited by pringle manoeuvre during radical excision on the prognosis of Hepatocellular Carcinoma (HCC)…
- Trial name
- NCT00725335
- Testing
- curative resection without Pringle, curative resection with Pringle manoeuvre
- Where
- China
- Volunteers
- 498 people
- Sponsor
- Southwest Hospital, China
Uncomplicated P. Vivax Mono-infection
Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax
This study is to conduct a clinical trial of tafenoquine combinations to compare the rates of therapeutic efficacy of dihydroartemisinin-piperaquine or artemether-lumefantrine with tafenoquine to chloroquine plus tafenoquine in…
- Trial name
- NCT07533136
- Testing
- Tafenoquine (TQ), Chloroquine (CQ), Dihydroartemisinin-piperaquine (DHA-PPQ)
- Where
- Thailand
- Volunteers
- 300 people
- Sponsor
- Walter Reed Army Institute of Research (WRAIR)
Hepatocellular Carcinoma, Neoplasm Metastasis
Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
The purpose of this study is to determine whether capecitabine is effective to prevent disease recurrence after curative hepatic resection in patients with hepatocellular carcinoma.
- Trial name
- NCT00561522
- Testing
- Capecitabine, No other preventive treatment
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Fudan University
Malaria, Malaria, Vivax
ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
In this area of Greater Mekong Subregion (GMS), vivax malaria is the most common kind of malaria. It can stay very long in the liver, and come out later to make another episode of illness.
- Conditions
- Malaria, Malaria, Vivax, Plasmodium Vivax Malaria
- Trial name
- ACTQ (NCT05788094)
- Testing
- Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose), Chloroquine plus Tafenoquine (450 mg adult dose), Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)
- Where
- Thailand
- Volunteers
- 606 people
- Sponsor
- Shoklo Malaria Research Unit
Hepatocellular Carcinoma
Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).
To prove that the efficacy and safety of 'MASCT group' is superior to 'non-treatment group' in patient undergone curative resection (RFA or operation) for hepatocellular carcinoma in China.
- Trial name
- HCC DC CTL (NCT02026362)
- Testing
- MASCT:Multiple Antigens Specific Cellular Therapy, The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- HRYZ Biotech Co.
Malaria, Vivax, G6PD Deficiency
Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand
The purpose of this prospective, observational study is to assess the operational feasibility of appropriate radical cure treatment for P.
- Trial name
- ARCTIC (NCT05753150)
- Testing
- Tafenoquine, Primaquine
- Where
- 9 sites in Thailand
- Volunteers
- 187 people
- Sponsor
- Dr. Prayuth Sudathip
Malaria, Malaria, Vivax
Short Course Radical Cure of P. Vivax Malaria in Nepal
This study is designed as a multicentre randomized, open label trial to assess the safety and efficacy of a low dose short course PQ treatment (3.5mg/kg total dose given over 7 days) in glucose-6-phosphate dehydrogenase (G6PD)…
- Conditions
- Malaria, Malaria, Vivax, Malaria,Falciparum
- Trial name
- NCT04079621
- Testing
- primaquine
- Where
- 2 sites in Nepal
- Volunteers
- 27 people
- Sponsor
- Menzies School of Health Research
Malaria, Vivax, Therapeutics
DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil
Plasmodium vivax can be cause of severe malaria and mortality. There are serious public health implications associated with cases of P.
- Trial name
- CuraVivax (NCT03208907)
- Testing
- CQ coadministered with PQ, DHA-PQP coadministered with PQ, CQ and PQ starting on Day 42
- Where
- Brazil
- Volunteers
- 419 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Neoplasms, Prostate, Prostate Cancer After a Radical Treatment
ARTS - AVODART After Radical Therapy For Prostate Cancer Study
ARI109924 will be a 2-year, multicentre, randomised, double-blind, placebo-controlled trial assessing the efficacy and safety of dutasteride in extending time to prostate specific antigen (PSA) doubling in men who have been…
- Trial name
- ARTS (NCT00558363)
- Testing
- Avodart
- Where
- 66 sites in Estonia, Finland and 7 more
- Volunteers
- 294 people
- Sponsor
- GlaxoSmithKline
Malaria, Malaria, Vivax
Vivax Elimination With Tafenoquine (VET) Study
Theoretically, so long as there is a sink-source for malaria, transmission could be sustained at very low level (even at sub-microscopic oscillation) and reintroduce malaria either as sporadic cases or as resurgent outbreak.
- Conditions
- Malaria, Malaria, Vivax, Plasmodium Vivax, Plasmodium Vivax Malaria
- Trial name
- VET (NCT06575647)
- Testing
- Tafenoquine
- Where
- Thailand
- Volunteers
- 1,242 people
- Sponsor
- Shoklo Malaria Research Unit
Malaria, Vivax
Study to Evaluate Primaquine for Radical Cure of Uncomplicated Plasmodium Vivax Malaria in Children
The main determinant of primaquine efficacy is the total dose of primaquine administered, rather than the dosing schedule. Infants and children younger than 4 years of age are at a higher risk of frequent relapses than older age…
- Trial name
- CHILDPRIM (NCT05044637)
- Testing
- Primaquine
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado